Bing Xia

5PUBLICATIONS
35CO-AUTHORS
Molecular targetsLiquid biopsiesTumour immunologyChemical and thermal processes in energy and combustionCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 10, 2026
Oncogenic EGFR rewires STING-TBK1 signalosomes to license DNA damage tolerance in NSCLC.

|Jan 06, 2026
Optimized patient-derived lung cancer organoids recapitulating the immune landscape for precision therapy evaluation.

Huayang Xing, Rui Liu, Yidan Chen

|May 16, 2025
Phase I/II Study of Tifcemalimab, an Anti-B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.

Ying Cheng, Jie Wang, Yan Yu

|Feb 28, 2024
IRF3 activates RB to authorize cGAS-STING-induced senescence and mitigate liver fibrosis.

Qirou Wu, Xiaohong Leng, Qian Zhang

|Feb 02, 2022
Postoperative radiotherapy for patients with completely resected stage IIIA-N2 non-small cell lung cancer: opt-in or opt-out.

Lucheng Zhu, Bing Xia, Shenglin Ma

Pageof 1

Frequent Collaborators

3 joint publications

Pinglong Xu

2 joint publications

Chen Mei

2 joint publications

Li Shen

2 joint publications

Xin-Hua Feng